Foyston Gordon & Payne Inc Reduces Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

Foyston Gordon & Payne Inc trimmed its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 25.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 94,961 shares of the company’s stock after selling 32,018 shares during the quarter. Henry Schein accounts for approximately 1.7% of Foyston Gordon & Payne Inc’s holdings, making the stock its 20th biggest holding. Foyston Gordon & Payne Inc’s holdings in Henry Schein were worth $6,571,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Ethic Inc. boosted its stake in Henry Schein by 13.1% during the fourth quarter. Ethic Inc. now owns 13,423 shares of the company’s stock worth $929,000 after buying an additional 1,552 shares during the period. D. E. Shaw & Co. Inc. lifted its holdings in shares of Henry Schein by 45.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 238,626 shares of the company’s stock worth $16,513,000 after acquiring an additional 75,118 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of Henry Schein by 21.0% during the 4th quarter. Deutsche Bank AG now owns 647,022 shares of the company’s stock worth $44,774,000 after purchasing an additional 112,408 shares during the period. Baird Financial Group Inc. grew its holdings in Henry Schein by 36.3% during the 4th quarter. Baird Financial Group Inc. now owns 5,438 shares of the company’s stock valued at $376,000 after purchasing an additional 1,447 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in Henry Schein during the 4th quarter valued at about $5,565,000. Institutional investors own 96.62% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Piper Sandler dropped their target price on Henry Schein from $83.00 to $77.00 and set an “overweight” rating for the company in a research report on Wednesday, April 30th. Jefferies Financial Group boosted their price objective on Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. UBS Group cut their price objective on Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 26th. Wells Fargo & Company decreased their target price on Henry Schein from $80.00 to $75.00 and set an “equal weight” rating for the company in a research report on Tuesday. Finally, StockNews.com cut shares of Henry Schein from a “buy” rating to a “hold” rating in a report on Thursday, April 17th. Six equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $79.30.

Insider Buying and Selling at Henry Schein

In related news, Director Philip A. Laskawy sold 2,604 shares of the company’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the sale, the director now directly owns 24,805 shares in the company, valued at $1,762,147.20. This represents a 9.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Bradford C. Connett sold 4,036 shares of Henry Schein stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the transaction, the chief executive officer now owns 62,688 shares in the company, valued at $4,460,251.20. This trade represents a 6.05 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.08% of the company’s stock.

Henry Schein Stock Performance

HSIC stock opened at $68.68 on Friday. Henry Schein, Inc. has a 1-year low of $60.56 and a 1-year high of $82.49. The business has a 50-day moving average price of $67.59 and a 200 day moving average price of $71.44. The company has a market capitalization of $8.41 billion, a P/E ratio of 28.26, a PEG ratio of 2.13 and a beta of 0.87. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Monday, May 5th. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.11 by $0.04. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.24 billion. During the same quarter in the previous year, the business posted $1.10 EPS. The company’s quarterly revenue was down .1% compared to the same quarter last year. As a group, equities research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.